Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 10-30% of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies.
This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken.
"Sinopsis" puede pertenecer a otra edición de este libro.
Amita Kashyap is Principal Investigator of the DST Project on Proliferation, Expression and Mutation Studies of K-ras Protooncogene and in silico drug designing against Non Small Cell Lung Cancer at CRRAO AIMSCS, University of Hyderabad. She has vast Biotech Corporate experience and has worked with several Biotechnology Research and Services Organizations. She has wide experience of handling various corporate R&D and service based Projects related to Molecular Biology, DNA Fingerprinting and Bioinformatics. She was one of the members of the BDRC Team in 2008 when the company delivered DNA Based Evidence collection training to Andhra Pradesh Police in various DTCs and PTCs Andhra Pradesh. For her novel work on Reverse Vaccinology she received Gold Medal at Biotech 2007 at Indian Institute of Toxicology Research, Council of Scientific and Industrial Research, Lucknow. She has been in the organizing and technical team of DNA 2009 at AP Police academy, DNA 2010 at Osmania University and DNA 2011 at GSI Lucknow. Mrs Amita has delivered more than 40 invited talks at various academic organizations and organized special session on Bioinformatics at PRIB Conference at Singapore 2007.
Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 10–30% of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies.
This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken.
"Sobre este título" puede pertenecer a otra edición de este libro.
EUR 28,91 gastos de envío desde Reino Unido a España
Destinos, gastos y plazos de envíoEUR 5,19 gastos de envío desde Reino Unido a España
Destinos, gastos y plazos de envíoLibrería: Ria Christie Collections, Uxbridge, Reino Unido
Condición: New. In. Nº de ref. del artículo: ria9789814585071_new
Cantidad disponible: Más de 20 disponibles
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 10-30% of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies.This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken. 80 pp. Englisch. Nº de ref. del artículo: 9789814585071
Cantidad disponible: 2 disponibles
Librería: moluna, Greven, Alemania
Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Amita Kashyap is Principal Investigator of the DST Project on Proliferation, Expression and Mutation Studies of K-ras Protooncogene and in silico drug designing against Non Small Cell Lung Cancer at CRRAO AIMSCS, University of Hyderabad. She has vast Biotec. Nº de ref. del artículo: 5843262
Cantidad disponible: Más de 20 disponibles
Librería: AHA-BUCH GmbH, Einbeck, Alemania
Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 10-30% of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies.This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken. Nº de ref. del artículo: 9789814585071
Cantidad disponible: 1 disponibles
Librería: Chiron Media, Wallingford, Reino Unido
Paperback. Condición: New. Nº de ref. del artículo: 6666-IUK-9789814585071
Cantidad disponible: 10 disponibles
Librería: Books Puddle, New York, NY, Estados Unidos de America
Condición: New. pp. 80. Nº de ref. del artículo: 26357317873
Cantidad disponible: 4 disponibles
Librería: Majestic Books, Hounslow, Reino Unido
Condición: New. Print on Demand pp. 80. Nº de ref. del artículo: 356221742
Cantidad disponible: 4 disponibles
Librería: Revaluation Books, Exeter, Reino Unido
Paperback. Condición: Brand New. 1st edition. 72 pages. 8.75x6.00x0.25 inches. In Stock. Nº de ref. del artículo: x-9814585076
Cantidad disponible: 2 disponibles
Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemania
Taschenbuch. Condición: Neu. Neuware -Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 10¿30% of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies.This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 80 pp. Englisch. Nº de ref. del artículo: 9789814585071
Cantidad disponible: 2 disponibles
Librería: Biblios, Frankfurt am main, HESSE, Alemania
Condición: New. PRINT ON DEMAND pp. 80. Nº de ref. del artículo: 18357317883
Cantidad disponible: 4 disponibles